Updates are available Correction dated 2026-05-23
Click to view Correction: https://doi.org/10.1007/s11136-026-04275-z
-
Authors
Gelhorn, Heather L. https://orcid.org/0000-0003-3566-1004
Cutts, Katelyn N.
Harrow, Brooke
Tait, Christopher
Saunders, Amanda
Fikre, Tsion
Han, Yipin
Zeringo, Nicholas A.
Van De Sande, Michiel
Tap, William
Gelderblom, Hans
Bernthal, Nicholas
-
Funding
Funding for this research was provided by:
Deciphera Pharmaceuticals (Deciphera Pharmaceuticals)
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 31 December 2025
First Online: 1 February 2026
Change Date: 24 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: Multiple formatting errors related to spacing, capitalization and table and figure headers and footers are corrected.
Change Date: 23 May 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11136-026-04275-z
Declarations
:
: Heather Gelhorn, Katelyn Cutts, Tsion Fikre and Yipin Han work for Evidera, a scientific research consultancy. Evidera was paid to conduct this work by Deciphera Pharmaceuticals, LLC. Brooke Harrow, Christopher Tait, Amanda Saunders, Nicholas A Zeringo are employees of Deciphera Pharmaceuticals, LLC. Michiel van de Sande reports institutional research funding from Implantcast GmbH and consulting/advisory roles for Merck, SynOx, and Deciphera Pharmaceuticals, LLC. Dr. Tap reports personal fees from: Daiichi Sankyo, Deciphera, Servier, Bayer Pharmaceuticals, Cogent, Amgen, AmMax Bio, Boehringer Ingelheim, BioAtla, Inhibrx, PharmaEssentia, Avacta, Ipsen, Sonata, Abbisko, Aadi, IMGT, Ikena, Curadev, Ratio, C4 Therapeutcis, Synox, Recordati. In addition, Dr. Tap has a patent Companion Diagnostic for CDK4 inhibitors—14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021–03 issued to MSKCC/SKI and Scientific Advisory Board—Certis Oncology Solutions, Stock Ownership, Co-Founder—Atropos Therapeutics, Stock Ownership, Scientific Advisory Board Innova Therapeutics Strategic Advisory Board Osteosarcoma Institute, and Chair, Scientific Advisory Board Avacta. Hans Gelderblom reports Institutional financial compensation for entering patients in TGCT studies form AmmaxBio, Deciphera, Abbisko and SynOx Therapeutics. Nicholas Bernthal reports Scientific Advisor to Daiichi Sankyo, Merck, Deciphera, ZimmerBiomet, Onkos Surgical.
: This study was approved by an institutional review board or ethics committee at each clinical site.
: Not applicable.
